
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Genmab and argenx combine antibody know-how
Genmab A/S and argenx will start their collaboration jointly launching two antibody programmes in immunology and oncology with the...

Phialogics AG bags pre-seed financing
Basel-based Phialogics AG, which was spun-off from Fraunhofer Institute for Immune Pathology and Immune Tolerance in 2021, has cashed in a pre-seed...

AI predicts an enzyme’s substrate
Researchers from Germany, Sweden and India have reported an AI method that predicts whether an enzyme can work with a specific substrate. In...

Macomics licences macrophage modulator to Ono
Whether Macomics Ltd nor Ono Pharmaceuticals Co Ltd disclosed any financial details about the deal under which Ono has the option to licence an...

Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
The latest Swiss Biotech Report, published at the end of April by the Swiss Biotech Association (SBA) in collaboration with EY and eight other...

Bayer AG is joining forces with Acuitas Therapeutics, Inc
Following the opening of an cell and gene therapy centre in the US, German Bayer AG opts for joining forces with Acuitas Therapeutics, Inc., a ...